Active Biotech

0.08 SEK

-0.62 %

Less than 1K followers

ACTI

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

-0.62 %

-49.69 %

-55.48 %

-21.54 %

-26.01 %

-50.31 %

-81.80 %

-83.39 %

-98.46 %

Active Biotech operates in the pharmaceutical industry and focuses on the development of innovative treatments for cancer and autoimmune diseases. The company researches new therapies that can improve patient outcomes and quality of life. The project portfolio includes both small, orally active immunomodulatory molecules and antibody-based immunotherapy. The company operates globally. Active Biotech was founded in 1998 and is headquartered in Lund.

Market cap

99.03M SEK

Turnover

128.02K SEK

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

19.11

2025

Extraordinary general meeting '26

12.2

2026

Annual report '25

7.5

2026

Interim report Q1'26

All

Webcasts

Press releases

ShowingAll content types

Regulatory press releaseyesterday

Active Biotech Interim Report Q3 2025

Press release11/3/2025, 3:30 PM

Preclinical data of tasquinimod in combination with T cell activation to be presented at ASH 2025

Regulatory press release10/17/2025, 6:35 PM

NOTICE OF EXTRAORDINARY GENERAL MEETING

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release10/17/2025, 6:30 PM

Active Biotech announces a fully secured rights issue of approximately SEK 70 million

Press release9/10/2025, 11:00 AM

Positive results from Active Biotech’s clinical phase I LION study to be presented at AAO 2025 in October

Press release8/25/2025, 2:40 PM

Redeye: Active Biotech Q2 2025 - On the Eve of a Laquinimod Deal

Regulatory press release8/21/2025, 6:30 AM

INTERIM REPORT Q2 2025

Press release7/8/2025, 6:30 AM

Active Biotech provides status update of its development programs

Press release6/30/2025, 3:15 PM

Interview with investigators of laquinimod eye drop study LION now available on Active Biotech’s website

Press release6/9/2025, 2:50 PM

Results from tasquinimod study in heavily pretreated patients with relapsed refractory multiple myeloma presented at ASCO 2025 available on Active Biotech’s website

Regulatory press release5/28/2025, 4:30 PM

Annual General Meeting of Active Biotech AB

Press release5/23/2025, 6:30 AM

Active Biotech reports study results with tasquinimod in heavily pre-treated patients with relapsed refractory multiple myeloma

Press release5/21/2025, 6:30 AM

Active Biotech announces patent for tasquinimod in myelofibrosis granted in Europe

Press release5/11/2025, 3:59 PM

Redeye: Active Biotech Q1 2025 - Important results with laquinimod

Regulatory press release5/8/2025, 6:30 AM

Active Biotech Interim Report Q1 2025

Regulatory press release5/5/2025, 7:00 AM

Active Biotech reports positive top-line results from the LION study on ocular absorption and distribution of laquinimod in the eye

Regulatory press release4/28/2025, 9:00 AM

NOTICE OF ANNUAL GENERAL MEETING

Regulatory press release4/7/2025, 9:00 AM

Annual Report 2024 Active Biotech AB (publ)

Press release3/10/2025, 7:30 AM

First patient dosed in the phase II study of tasquinimod in myelofibrosis in the US

Press release2/24/2025, 9:00 AM

First patient enrolled in the HO172 clinical study of tasquinimod in myelofibrosis

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.